22 results found.

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Mixed Muellerian Cancer, Cervical Cancer, Ovarian Cancer, Breast Clinical Trial using Carboplatin; Olaparib; Treatment Effect

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers.
Carboplatin; Olaparib; Treatment Effect

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Biochemical-recurrent Only Epithelial Ovarian Cancer, Primary Per Clinical Trial using INCB024360; tamoxifen

Incyte Corporation - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy.
INCB024360; tamoxifen

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Can Clinical Trial using Tivozanib

Northwestern University - Recruiting 18 years or older.
- The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Tivozanib

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using CRLX101

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer.
CRLX101

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Ovarian Cancer, Fallopian Tubes Cancer, or Peritoneal Cancer Clinical Trial using Secondary Cytoreductive Surgery; Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC); platinum-based systemic chemotherapy postoperatively

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Secondary Cytoreductive Surgery; Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC); platinum-based systemic chemotherapy postoperatively

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clinical Trial using Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30).
Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Trial using intravenous docetaxel with intraperitoneal oxaliplatin; intravenous oxaliplatin with intraperitoneal docetaxel

University of Pittsburgh - Recruiting 18 years or older.
- Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer.
intravenous docetaxel with intraperitoneal oxaliplatin; intravenous oxaliplatin with intraperitoneal docetaxel

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using RAD001; bevacizumab

University of Pittsburgh - Recruiting 18 years or older.
- Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital.
RAD001; bevacizumab

Epithelial Ovarian Cancer, Which is Platinum Resistant or Refract Clinical Trial using Pazopanib and Cyclophosphamid

University Hospital Heidelberg - Recruiting 18 years or older.
- A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.
Pazopanib and Cyclophosphamid